NovelStem International Corp.

NovelStem International Corp. is a U.S.-based holding company whose principal assets have included interests in NewStem and NetCo, along with rights tied to NewStem-related intellectual property. The company’s business history is centered on ownership, licensing, and monetization of biotechnology assets rather than operating a traditional retail store business.

0.01

— NovelStem International Corp.
%
Holding company investments0% Ownership interests in operating or development-stage portfolio entities and related equity-method investments.
Intellectual property monetization rights0% Rights associated with NewStem technology, licenses, and related intangible assets.
Administrative fee income100% Fees charged to affiliated entities for administrative support services.

NovelStem does not operate a conventional customer-facing retail business; its economic counterparties are affiliated...

  • Affiliated entitiesprimary

    Paid annual administrative fees for support services through 2024.

  • Shareholdersprimary

    Provide financial support through equity or bridge funding to sustain the holding company.

  • Lenders and noteholderssecondary

    Provide debt financing and convertible debt when external capital is needed.

  • Licensing and monetization counterpartiesprimary

    Counterparties involved in monetizing NewStem-related licenses and intangible assets.

The company is incorporated in the United States, but its operating history has been tied to Israeli biotechnology...

  • •United States is the corporate base and reporting jurisdiction
  • •Israeli biotech assets are central to the NewStem-related value proposition
  • •No operating retail store network is disclosed in the reports
  • •No country-level revenue breakdown was disclosed in the excerpts

The company’s strategic focus is to monetize the former NewStem license and related intangible assets while preserving...

01
Monetize NewStem-related intellectual propertyshort-term

The company’s primary asset value is tied to legacy biotech rights and intangible assets.

02
Secure external funding and shareholder supportshort-term

The holding company needs capital to remain a going concern and pursue asset monetization.

03
Maximize recovery from legacy investmentsmedium-term

Portfolio interests and liquidation proceeds can offset prior losses and reduce impairment exposure.

The company faces substantial going-concern and financing risk because it depends on external capital and successful...

critical

Going-concern dependence on external financing

Operations require continued shareholder support and additional outside funding.

Scope
Holding-company liquidity and survival
Materiality
high
critical

Failure to monetize NewStem-related assets

The company’s primary value creation path depends on realizing proceeds from legacy biotech IP.

Scope
Former NewStem license and intangible assets
Materiality
high
high

Impairment of investments and intangibles

The company has already recorded full impairment on NewStem investment and may face further write-downs.

Scope
Equity-method investments and intangible assets
Materiality
high
medium

Counterparty and collectability risk

Administrative fees and related-party receivables may be uncollectible, and liquidation proceeds are uncertain.

Scope
Affiliates, notes receivable, liquidation recoveries
Materiality
medium
Impairment of NewStem investment and intangibles
Can create large non-cash swings in earnings and asset carrying values
Equity-method accounting
Net income can move materially even without operating revenue
Going-concern assessment
Affects disclosure, valuation assumptions, and investor risk assessment
Bad debt and receivable collectability
Can reduce earnings and signal counterparty weakness

International Stem Cell CORP

ISCO · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

Generation Bio Co.

Pharmaceutical Preparations

EXICURE, INC.

XCUR · Pharmaceutical Preparations

Mosaic ImmunoEngineering Inc.

CPMV · Biological Products, (No Diagnostic Substances)

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

: 29/04/2026